Galderma has announced that the European Commission has granted Marketing Authorisation in Europe for Mirvaso® (brimonidine) 3 mg/g gel. Mirvaso is an alpha-2 adrenergic receptor agonist that acts rapidly and can

This content is restricted to registered user. If you are an existing user, please log in. New users may register for free.

Existing Users Log In
   
Forgot password? Click here to reset
New User Registration
 
 
 
 
 
 
Please indicate that you agree to the Terms of Service *
*Required field